Latest Pro Medicus (ASX:PME) News

Imugene, Vitasora and Adherium led a volatile week in healthcare shares, as trial news and software rollouts battled capital raisings, legal issues and weak sentiment in smaller biotech names. Big contracts, takeover steps and record earnings kept the sector busy, but several stocks still fell even after reporting clear operational progress.

Pro Medicus’ US arm Visage Imaging has landed a significant 7-year, A$90 million contract to deploy its cloud-based Visage 7 platform across Beth Israel Lahey Health, marking another major foothold in North America's healthcare imaging market.

Big gains came from contracts, approvals and takeover interest, while several capital raisings and debt deals drew a cooler response. Diagnostics, radiopharma and medtech led the week, with buyers rewarding companies that showed clear sales, supply or hospital access.

Pro Medicus has secured a 5-year, A$37 million contract renewal with Northwestern Medicine, featuring higher minimum usage commitments and increased fees per transaction, reflecting growth in exam volumes.

Rare earths, lithium and antimony stocks drove the week, while a handful of capital raisings and profit warnings hit hard. The biggest gains came from drilling wins and deal news. The sharpest falls came where investors faced dilution, weaker earnings or takeover friction.

Small-cap healthcare names produced the biggest share-price swings this week, while larger names advanced on sales growth, trial progress and fresh contracts. Investors rewarded companies that showed clear commercial traction, but fundraising and weak follow-through punished others.

Pro Medicus Limited’s U.S. subsidiary has signed a five-year, A$23 million contract to implement its cloud-based Visage 7 Enterprise Imaging Platform across the University of Maryland Medical System. The rollout is planned to begin immediately, with go-live targeted for early 2027.

Big moves came from point-of-care testing and a sharp sell-off in two names despite upbeat news. Meanwhile, several smaller caps pushed trials and regulatory files forward, giving investors clear dates to watch.

Pro Medicus Limited has announced an on-market buy-back program targeting up to 10% of its ordinary shares, aiming to return capital to shareholders without requiring approval.

A single biotech result reset expectations in minutes, while gold and critical minerals kept investors busy on deals, drilling and funding. The week’s biggest moves came from one trial being stopped, a miner losing altitude after heavy selling, and a U.S. tungsten stock hit hard on risk-off trading.

A brutal clinical trial stop wiped out Immutep, while Adherium surged on faster Remote Patient Monitoring growth. Across the rest of healthcare, investors paid up for proof: accredited tests, enrolled Phase III studies, and signed multi-year contracts.

Pro Medicus Limited’s U.S. subsidiary has locked in two significant 5-year contract renewals worth a combined minimum of A$40 million, reinforcing its position in the competitive medical imaging market.